Novo Nordisk A/S (NVO) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Q3 2025 Novo Nordisk Earnings Conference Call. At this time all participants are in a listen-only mode. After the speaker's presentation there'll be a question and answer session. To ask a question during the session you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question please press star 1 and 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jakob Rode, Head of Investor Relations. Please go ahead. Thank you. Welcome to this NOVA Nordisk earnings call for the first nine months of 2025. My name is Jakob Rode, and I'm the Head of Investor Relations. With me today, I have CEO of NOVA Nordisk, Mike Duster, Executive Vice President, Product and Portfolio Strategy, Ludwig Helfgott, Executive Vice President, U.S. Operations, Dave Maul, Executive Vice President Research and Development and Chief Scientific Officer Martin Holst-Lange and Chief Financial Officer Carsten Munkhausen. All speakers will be available for the Q&A session. Please note that the call is being webcasted live and a recording will be available on our website as well. The call is scheduled to last a little more than one hour. Please turn to the next slide. The presentation is structured as outlined on slide two. Please note that all sales and operating profit growth statements will be at constant exchange rates unless otherwise specified. Next slide, please. We need to advise you that this all will contain forward-looking statements. These are subject to risks and uncertainty that could cause actual results to differ materially from expectations. For further inform...